Abstract
Granulocyte colony-stimulating factor (G-CSF) can be administered after a peripheral blood stem cell transplantation with the aim of accelerating neutrophil recovery. In a randomized, single-blind study we studied a new administration schedule of G-CSF in this context.
Publication types
-
Clinical Trial
-
Comparative Study
-
Letter
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adult
-
Antigens, CD34 / analysis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Drug Administration Schedule
-
Female
-
Graft Survival / drug effects
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Hematologic Neoplasms / blood
-
Hematologic Neoplasms / drug therapy
-
Hematologic Neoplasms / surgery
-
Humans
-
Lenograstim
-
Male
-
Middle Aged
-
Peripheral Blood Stem Cell Transplantation*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Single-Blind Method
-
Transplantation, Autologous
-
Treatment Outcome
Substances
-
Antigens, CD34
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Lenograstim